Perspectives in melanoma

Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alfredo Budillon, Michael A. Davies, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Silvia Formenti, Thomas F. Gajewski, Claus Garbe, Omid Hamid, Roger S. Lo, Jason J. Luke, Oliver Michielin, Giuseppe Palmieri, Laurence Zitvogel, Francesco M. Marincola, Giuseppe Masucci, Corrado Caracò & 2 others Magdalena Thurin, Igor Puzanov

Research output: Contribution to journalArticle

Abstract

Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers they have yet to be fully characterized and implemented clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in melanoma have led to the use of genome sequencing and gene expression for development of multi-marker assays that show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical studies is to achieve incremental improvements through the development and identification of optimal treatment regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of biomarkers to improve immune response. These and other topics in the management of melanoma were the focus of discussions at the fourth Melanoma Bridge meeting (November 29th-December 1st, 2018, Naples, Italy), which is summarised in this report.

Original languageEnglish
Article number234
JournalJournal of Translational Medicine
Volume17
Issue number1
DOIs
Publication statusPublished - Jul 22 2019

Fingerprint

Italy
Tumors
Melanoma
Biomarkers
Neoplasms
Tumor Microenvironment
Therapeutics
Immunotherapy
Patient Selection
Biopsy
Immunity
Gene expression
Assays
Genes
Translational Medical Research
Association reactions
Genome
Gene Expression

Keywords

  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • Biomarkers
  • BRAF inhibitor
  • Combination strategies
  • Immunotherapy
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Target therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Perspectives in melanoma : Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). / Ascierto, Paolo A.; Agarwala, Sanjiv S.; Botti, Gerardo; Budillon, Alfredo; Davies, Michael A.; Dummer, Reinhard; Ernstoff, Marc; Ferrone, Soldano; Formenti, Silvia; Gajewski, Thomas F.; Garbe, Claus; Hamid, Omid; Lo, Roger S.; Luke, Jason J.; Michielin, Oliver; Palmieri, Giuseppe; Zitvogel, Laurence; Marincola, Francesco M.; Masucci, Giuseppe; Caracò, Corrado; Thurin, Magdalena; Puzanov, Igor.

In: Journal of Translational Medicine, Vol. 17, No. 1, 234, 22.07.2019.

Research output: Contribution to journalArticle

Ascierto, PA, Agarwala, SS, Botti, G, Budillon, A, Davies, MA, Dummer, R, Ernstoff, M, Ferrone, S, Formenti, S, Gajewski, TF, Garbe, C, Hamid, O, Lo, RS, Luke, JJ, Michielin, O, Palmieri, G, Zitvogel, L, Marincola, FM, Masucci, G, Caracò, C, Thurin, M & Puzanov, I 2019, 'Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)', Journal of Translational Medicine, vol. 17, no. 1, 234. https://doi.org/10.1186/s12967-019-1979-z
Ascierto, Paolo A. ; Agarwala, Sanjiv S. ; Botti, Gerardo ; Budillon, Alfredo ; Davies, Michael A. ; Dummer, Reinhard ; Ernstoff, Marc ; Ferrone, Soldano ; Formenti, Silvia ; Gajewski, Thomas F. ; Garbe, Claus ; Hamid, Omid ; Lo, Roger S. ; Luke, Jason J. ; Michielin, Oliver ; Palmieri, Giuseppe ; Zitvogel, Laurence ; Marincola, Francesco M. ; Masucci, Giuseppe ; Caracò, Corrado ; Thurin, Magdalena ; Puzanov, Igor. / Perspectives in melanoma : Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). In: Journal of Translational Medicine. 2019 ; Vol. 17, No. 1.
@article{32312a15f5e247edb5f7ef9c8d6ccffd,
title = "Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)",
abstract = "Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers they have yet to be fully characterized and implemented clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in melanoma have led to the use of genome sequencing and gene expression for development of multi-marker assays that show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical studies is to achieve incremental improvements through the development and identification of optimal treatment regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of biomarkers to improve immune response. These and other topics in the management of melanoma were the focus of discussions at the fourth Melanoma Bridge meeting (November 29th-December 1st, 2018, Naples, Italy), which is summarised in this report.",
keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, Biomarkers, BRAF inhibitor, Combination strategies, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Target therapy",
author = "Ascierto, {Paolo A.} and Agarwala, {Sanjiv S.} and Gerardo Botti and Alfredo Budillon and Davies, {Michael A.} and Reinhard Dummer and Marc Ernstoff and Soldano Ferrone and Silvia Formenti and Gajewski, {Thomas F.} and Claus Garbe and Omid Hamid and Lo, {Roger S.} and Luke, {Jason J.} and Oliver Michielin and Giuseppe Palmieri and Laurence Zitvogel and Marincola, {Francesco M.} and Giuseppe Masucci and Corrado Carac{\`o} and Magdalena Thurin and Igor Puzanov",
year = "2019",
month = "7",
day = "22",
doi = "10.1186/s12967-019-1979-z",
language = "English",
volume = "17",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Perspectives in melanoma

T2 - Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

AU - Ascierto, Paolo A.

AU - Agarwala, Sanjiv S.

AU - Botti, Gerardo

AU - Budillon, Alfredo

AU - Davies, Michael A.

AU - Dummer, Reinhard

AU - Ernstoff, Marc

AU - Ferrone, Soldano

AU - Formenti, Silvia

AU - Gajewski, Thomas F.

AU - Garbe, Claus

AU - Hamid, Omid

AU - Lo, Roger S.

AU - Luke, Jason J.

AU - Michielin, Oliver

AU - Palmieri, Giuseppe

AU - Zitvogel, Laurence

AU - Marincola, Francesco M.

AU - Masucci, Giuseppe

AU - Caracò, Corrado

AU - Thurin, Magdalena

AU - Puzanov, Igor

PY - 2019/7/22

Y1 - 2019/7/22

N2 - Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers they have yet to be fully characterized and implemented clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in melanoma have led to the use of genome sequencing and gene expression for development of multi-marker assays that show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical studies is to achieve incremental improvements through the development and identification of optimal treatment regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of biomarkers to improve immune response. These and other topics in the management of melanoma were the focus of discussions at the fourth Melanoma Bridge meeting (November 29th-December 1st, 2018, Naples, Italy), which is summarised in this report.

AB - Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers they have yet to be fully characterized and implemented clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in melanoma have led to the use of genome sequencing and gene expression for development of multi-marker assays that show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical studies is to achieve incremental improvements through the development and identification of optimal treatment regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of biomarkers to improve immune response. These and other topics in the management of melanoma were the focus of discussions at the fourth Melanoma Bridge meeting (November 29th-December 1st, 2018, Naples, Italy), which is summarised in this report.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - Biomarkers

KW - BRAF inhibitor

KW - Combination strategies

KW - Immunotherapy

KW - MEK inhibitor

KW - Melanoma

KW - Neoadjuvant

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85069781494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069781494&partnerID=8YFLogxK

U2 - 10.1186/s12967-019-1979-z

DO - 10.1186/s12967-019-1979-z

M3 - Article

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 234

ER -